Radiation Proctitis Market

Radiation Proctitis Market (Indication: Acute Radiation Proctitis and Chronic Radiation Proctitis; and Therapy: Oral Therapy, Ablative Procedures, Hyperbaric Oxygen Therapy,Formalin, and Surgery) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2020-2030

HBOT, IV Vitamin Drops to Boost Patient Immunity amid COVID-19 Pandemic

Healthcare facilities such as the Hyperbaric Medical Solutions is taking extra preventive steps to mitigate the risks of the coronavirus pandemic to ensure all patients are offered clean and safe environments. Stakeholders in the radiation proctitis market are increasing efforts to boost the availability for hyperbaric oxygen therapy (HBOT), which is being associated with enhancing the immune system in the wake of the COVID-19 outbreak.

Companies in the radiation proctitis market are maintaining steady supply of intravenous (IV) vitamin drips, which help to strengthen the immunity of patients and help in detoxification. However, a slowdown in the global economy may have affected revenue collections in healthcare facilities. Hence, healthcare companies should adopt flexible business strategies, and team up with their stakeholders in the value chain to manage investments and product launches.

radiation proctitis market segmentation

Request a sample to get extensive insights into the Radiation Proctitis Market 

Alternative Trials Design Help Overcome Uncertainties in Controlled Trials for HBOT

HBOT is emerging as the gold standard for treating radiation toxicity. However, this treatment is being associated with side effects such as transient myopia, fatigue, and barotrauma. Moreover, patients with severe complaints refrain from participating and even opt out of randomized controlled trials. Hence, companies in the radiation proctitis market are collaborating with research institutes to create alternative trials design in order to overcome the issues in trials within cohorts design.

The approval of the U.S.-based FDA (Food & Drug Association) for HBOT is creating incremental opportunities for companies in the radiation proctitis market. This explains why the market is expected to reach US$ 748.5 Mn by 2030.

To understand how our report can bring difference to your business strategy, Ask for a brochure

Topical Corticosteroids, Antidiarrheal Therapies Improve Medical Outcomes

Improvements in radiotherapy techniques are enabling superior delivery of radiation doses, and have the potential to easily reduce cases of both chronic and acute proctitis. Despite these advancements, the radiation proctitis market is projected to register a favorable CAGR of ~7% during the assessment period, owing to a high prevalence of radiation toxicity.

Healthcare providers in the radiation proctitis market are gaining proficiency iron substitution therapies. Manufacturers are boosting their output capacities in topical corticosteroids, sucralfate injections, and increasing R&D in antidiarrheal therapies, since the latter is gaining popularity as an aggressive means for patient care.

Intraperitoneal Injections, Colostomy Translate into Growth Opportunities for Healthcare Providers

Apart from oral therapies, companies and healthcare providers in the radiation proctitis market are offering remedial laser techniques in cases of continuous rectal bleeding. Clinicians are attempting formaldehyde administration before the surgical therapy. Healthcare professionals are conducting a descending or transverse colostomy for patients when surgery is required. Companies in the radiation proctitis market are increasing the availability of intraperitoneal injections of formalin.

Novel methods of cold therapy and radiofrequency ablation (RFA) are grabbing the attention of healthcare providers. Colostomy is gaining prominence as an effective and safe procedure for treating rectal ulcer of chronic radiation proctitis patients. Colostomy helps to control rectal bleeding and effectively relieve pain in patients.

Prostaglandins Aid in Healing of Inflammation, Wounds in Prostate Cancer Patients

The high prevalence of hemorrhagic radiation proctitis is acting as a key driver for the expansion of the radiation proctitis market. However, the lack of consensus for the management of hemorrhagic radiation proctitis is likely to inhibit market growth. Despite the challenges, clinicians are adopting rectal resection as an available option for hemorrhagic radiation proctitis management.

Healthcare companies in the radiation proctitis market are increasing their R&D in prostaglandins that aid in the healing of inflammation and wounds. This has led to the popularity of misoprostol, which is found to be efficacious in treating complications that arise in patients with prostate cancer that receive radiation therapy. Misoprostol rectal suppositories are being highly publicized for reducing the complications associated with acute and chronic radiation proctitis.

radiation proctitis market infographic

Stuck in a neck-to-neck competition with other brands? Request a custom report on Radiation Proctitis Market 

Analysts’ Viewpoint

Healthcare providers are providing uncompromised care services to radiation proctitis patients despite reduced hospital and clinical visits during the ongoing COVID-19 outbreak. Even as the National Comprehensive Cancer Network (NCCN) is setting guidelines for the Radiation Therapy Compendium™ Development, companies and healthcare providers are increasing efforts to gain proficiency in HBOT. However, HBOT is associated with oxygen toxicity and seizures. Hence, companies and healthcare professionals in the radiation proctitis market should encourage patients to participate in controlled trials and alternative trial design to improve medical outcomes. As such, manufacturers are increasing their focus in stool softeners and treatments that heal tissues in order to minimize patient complications.

Radiation Proctitis Market: Overview

  • According to Transparency Market Research’s latest report on the global radiation proctitis market for the historical period 20182019 and forecast period 20202030, surge in adoption of advanced technologies to treat cancer is projected to boost the growth of the global market
  • Radiation proctitis is inflammation of the rectum due to exposure of X rays or other ionizing radiation. The management of radiation proctitis is divided into invasive and non-invasive treatment. Non-invasive treatment includes anti-inflammatory agents, sucralfate, short-chain fatty acids, hyperbaric, and antioxidants.

Rise in Prevalence of Cancer to Drive Radiation Proctitis Market

  • Increase in incidence of prostate cancer, owing to genetic alterations & family history drives the demand for advanced therapy, which, in turn, boosts the growth of the global radiation proctitis market. Prostate cancer is the second most frequently diagnosed cancer in men and the fifth leading cause of death globally. The incidence of anal cancer has increased significantly in the last decade, and is currently estimated to be ~1.5 per 100,000 in the general population of the U.S., particularly in certain population subgroups.

Increase in Adoption of Radiation Therapy to Treat Cancer to Propel Radiation Proctitis Market

  • Over 14 million new cases of cancer are diagnosed globally each year. Radiation therapy (RT) has the potential to improve the rates of cure of 3.5 million people and provide palliative relief for an additional 3.5 million people.
  • Radiotherapy is the most commonly use treatment for cancer regimen in countries in the West. Technological advancements with a better understanding of tumor biology at the molecular, cellular, physiological, and immunological levels have improved the treatment efficacy of radiotherapy. This is anticipated to drive the adoption of radiation therapy, which is expected to boost the global radiation proctitis market.

High Cost of Hyperbaric Oxygen Therapy to Hamper Radiation Proctitis Market

  • Cost is one of the major factors that influences the selection of treatment. Hyperbaric oxygen therapy is one of the few treatments for patients with severe radiation-induced symptoms, which include proctitis and cystitis with bleeding. Currently, hyperbaric oxygen therapy is expensive and therefore, the economically weak cannot afford it, despite the significant therapeutic effects. This acts as a major restraint of the global radiation proctitis market.

Radiation Proctitis Market: Competition Landscape

  • This report profiles major players operating in the global radiation proctitis market based on various attributes and recent developments
  • The global radiation proctitis market is highly fragmented, with the presence of a large number of global as well as regional players
  • Leading players operating in the global radiation proctitis market include
    • Allergan plc
    • Teva Pharmaceutical Industries Ltd.
    • Amneal Pharmaceuticals, Inc.
    • Pfizer, Inc.
    • Mylan, Inc. (Viatris)
    • Sanofi
    • Johnson & Johnson (Johnson & Johnson Consumer, Inc.)
    • Sun Pharmaceutical Industries Ltd.
    • Environmental Tectonics Corporation
    • Sechrist Industries, Inc.

Radiation Proctitis Market: Key Developments

  • Key players in the global radiation proctitis market are engaged in regulatory approvals, technologically advanced products, launch of new products, and acquisition & collaborative agreements with other companies. These strategies are aimed at strengthening the product portfolio and investing in research & development. A few expansion strategies adopted by players operating in the global radiation proctitis market are:
    • In December 2020, Pfizer, Inc. and Myovant Sciences entered into a collaboration to develop and commercialize relugolix. It is an oral gonadotropin-releasing hormone (GnRH) receptor antagonist in women’s health and oncology in the U.S. and Canada.
    • In December 2019, Amneal entered into a definitive agreement under which, Amneal will acquire a 65.1% majority interest in AvKARE and its related affiliate doing business. The deal was valued at US$ 340 Mn.
    • In August 2019, Sun Pharmaceutical Industries Ltd. entered into a collaboration with China Medical System Holdings. This collaboration enabled the company to enter into the generic pharmaceutical market in China.
  • The report on the global radiation proctitis market discussed individual strategies, followed by company profiles of manufacturers of radiation proctitis products. The competition landscape section has been included in the report to provide readers with a dashboard view and a company market share analysis of key players operating in the global radiation proctitis market.

Radiation Proctitis Market – Segmentation

Indication
  • Acute Radiation Proctitis
  • Chronic Radiation Proctitis
Therapy
  • Oral Therapy
    • Antidiarrheals
    • Anti-inflammatory Agents
    • Others
  • Ablative Procedures
  • Hyperbaric Oxygen Therapy
  • Formalin
  • Surgery
Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

Frequently Asked Questions

What is the total market worth of radiation proctitis market?

Radiation proctitis market is expected to reach US$ 748.5 Mn by 2030

What is the anticipated CAGR of the radiation proctitis market in the forecast period?

Radiation proctitis market is projected to expand at a CAGR of ~7% from 2020 to 2030

What are the key driving factors for the growth of the radiation proctitis market?

Radiation proctitis market is driven by increase in incidence of urinary diseases

Which is the rising prominent segment in the radiation proctitis market?

The acute radiation proctitis segment dominated the global radiation proctitis market, and the trend is projected to continue during the forecast period

Who are the key players in the global radiation proctitis market?

Key players in the global radiation proctitis market are Allergan plc, Teva Pharmaceutical Industries Ltd., Amneal Pharmaceuticals, Inc., Pfizer, Inc., Mylan, Inc.

    1. Preface 

        1.1. Market Definition and Scope

        1.2. Market Segmentation

        1.3. Key Research Objectives

        1.4. Research Highlights

    2. Assumptions and Research Methodology

    3. Executive Summary: Global Radiation Proctitis market

    4. Market Overview

        4.1. Introduction

        4.2. Overview

        4.3. Market Dynamics

            4.3.1. Drivers

            4.3.2. Restraints

            4.3.3. Opportunities

        4.4. Global Radiation Proctitis Market Analysis and Forecast, 2018–2030

            4.4.1. Market Revenue Projections (US$ Mn)

        4.5. Porter’s Five Force Analysis 

    5. Market Outlook

        5.1. Prevalence of Urinary Incontinence, by Region 

        5.2. Key Industry Events

        5.3. Regulatory Scenario

        5.4. Technological Advancements

        5.5. Key Success Factors of Top Players

    6. Global Radiation Proctitis Market Value (US$ Mn) Forecast, by Indication

        6.1. Introduction & Definition 

        6.2. Global Radiation Proctitis Market Value Forecast, by Indication, 2018–2030

            6.2.1. Acute Radiation Proctitis

            6.2.2. Chronic Radiation Proctitis 

        6.3. Global Radiation Proctitis Market Attractiveness Analysis, by Indication

    7. Global Radiation Proctitis Market Value (US$ Mn) Forecast, by Therapy

        7.1. Introduction & Definition 

        7.2. Global Radiation Proctitis Market Value Forecast, by Therapy, 2018–2030

            7.2.1. Oral Therapy

                7.2.1.1. Antidiarrheals

                7.2.1.2. Anti-inflammatory Agents

                7.2.1.3. Others

            7.2.2. Ablative Procedures

            7.2.3. Hyperbaric Oxygen Therapy

            7.2.4. Formalin

            7.2.5. Surgery

    8. Global Radiation Proctitis Market Value (US$ Mn) Forecast, by Region

        8.1. Introduction 

        8.2. Radiation Proctitis Market Value Forecast, by Region, 2018–2030

            8.2.1. North America

            8.2.2. Europe

            8.2.3. Asia Pacific

            8.2.4. Latin America

            8.2.5. Middle East & Africa

        8.3. Global Radiation Proctitis Market Attractiveness Analysis, by Region

    9. North America Radiation Proctitis Market Analysis and Forecast 

        9.1. Introduction

        9.2. North America Radiation Proctitis Market Value Forecast, by Indication, 2018–2030

            9.2.1. Acute Radiation Proctitis

            9.2.2. Chronic Radiation Proctitis

        9.3. North America Radiation Proctitis Market Value Forecast, by Therapy, 2018–2030

            9.3.1. Oral Therapy

                9.3.1.1. Antidiarrheals

                9.3.1.2. Anti-inflammatory Agents

                9.3.1.3. Others

            9.3.2. Ablative Procedures

            9.3.3. Hyperbaric Oxygen Therapy

            9.3.4. Formalin

            9.3.5. Surgery

        9.4. North America Radiation Proctitis Market Value Forecast, by Country/Sub-region, 2018–2030

            9.4.1. U.S.

            9.4.2. Canada

        9.5. North America Radiation Proctitis Market Attractiveness Analysis

            9.5.1. By Indication

            9.5.2. By Therapy 

            9.5.3. By Country/Sub-region

    10. Europe Radiation Proctitis Market Analysis and Forecast 

        10.1. Introduction

        10.2. Europe Radiation Proctitis Market Value Forecast, by Indication, 2018–2030

            10.2.1. Acute Radiation Proctitis

            10.2.2. Chronic Radiation Proctitis

        10.3. Europe Radiation Proctitis Market Value Forecast, by Therapy, 2018–2030

            10.3.1. Oral Therapy

                10.3.1.1. Antidiarrheals

                10.3.1.2. Anti-inflammatory Agents

                10.3.1.3. Others

            10.3.2. Ablative Procedures

            10.3.3. Hyperbaric Oxygen Therapy

            10.3.4. Formalin

            10.3.5. Surgery

        10.4. Europe Radiation Proctitis Market Value Forecast, by Country/Sub-region, 2018–2030

            10.4.1. Germany

            10.4.2. U.K.

            10.4.3. France

            10.4.4. Spain

            10.4.5. Italy 

            10.4.6. Rest of Europe

        10.5. Europe Radiation Proctitis Market Attractiveness Analysis

            10.5.1. By Indication

            10.5.2. By Therapy 

            10.5.3. By Country/Sub-region

    11. Asia Pacific Radiation Proctitis Market Analysis and Forecast 

        11.1. Introduction

        11.2. Asia Pacific Radiation Proctitis Market Value Forecast, by Indication, 2018–2030

            11.2.1. Acute Radiation Proctitis

            11.2.2. Chronic Radiation Proctitis

        11.3. Asia Pacific Radiation Proctitis Market Value Forecast, by Therapy, 2018–2030

            11.3.1. Oral Therapy

                11.3.1.1. Antidiarrheals

                11.3.1.2. Anti-inflammatory Agents

                11.3.1.3. Others

            11.3.2. Ablative Procedures

            11.3.3. Hyperbaric Oxygen Therapy

            11.3.4. Formalin

            11.3.5. Surgery

        11.4. Asia Pacific Radiation Proctitis Market Value Forecast, by Country/Sub-region, 2018–2030

            11.4.1. Japan

            11.4.2. China

            11.4.3. India

            11.4.4. Australia & New Zealand

            11.4.5. Rest of Asia Pacific

        11.5. Asia Pacific Radiation Proctitis Market Attractiveness Analysis

            11.5.1. By Indication

            11.5.2. By Therapy 

            11.5.3. By Country/Sub-region

    12. Latin America Radiation Proctitis Market Analysis and Forecast 

        12.1. Introduction

        12.2. Latin America Radiation Proctitis Market Value Forecast, by Indication, 2018–2030

            12.2.1. Acute Radiation Proctitis

            12.2.2. Chronic Radiation Proctitis

        12.3. Latin America Radiation Proctitis Market Value Forecast, by Therapy, 2018–2030

            12.3.1. Oral Therapy

            12.3.2. Ablative Procedures

            12.3.3. Hyperbaric Oxygen Therapy

            12.3.4. Formalin

            12.3.5. Surgery

        12.4. Latin America Radiation Proctitis Market Value Forecast, by Country/Sub-region, 2018–2030

            12.4.1. Brazil

            12.4.2. Mexico

            12.4.3. Rest of Latin America

        12.5. Latin America Radiation Proctitis Market Attractiveness Analysis

            12.5.1. By Indication

            12.5.2. By Therapy 

            12.5.3. By Country/Sub-region

    13. Middle East & Africa Radiation Proctitis Market Analysis and Forecast 

        13.1. Introduction

        13.2. Middle East & Africa Radiation Proctitis Market Value Forecast, by Indication, 2018–2030

            13.2.1. Acute Radiation Proctitis

            13.2.2. Chronic Radiation Proctitis

        13.3. Middle East & Africa Radiation Proctitis Market Value Forecast, by Therapy, 2018–2030

            13.3.1. Oral Therapy

                13.3.1.1. Antidiarrheals

                13.3.1.2. Anti-inflammatory Agents

                13.3.1.3. Others

            13.3.2. Ablative Procedures

            13.3.3. Hyperbaric Oxygen Therapy

            13.3.4. Formalin

            13.3.5. Surgery

        13.4. Middle East & Africa Radiation Proctitis Market Value Forecast, by Country/Sub-region, 2018–2030

            13.4.1. GCC Countries

            13.4.2. South Africa

            13.4.3. Rest of Middle East & Africa

        13.5. Middle East & Africa Radiation Proctitis Market Attractiveness Analysis

            13.5.1. By Indication

            13.5.2. By Therapy 

            13.5.3. By Country/Sub-region

    14. Competition Landscape

        14.1. Global Radiation Proctitis Market Share Analysis, by Company, 2019

        14.2.  Company Profiles

            14.2.1. Allergan plc 

                14.2.1.1. Company Description

                14.2.1.2. Business Overview

                14.2.1.3. Financial Overview

                14.2.1.4. Strategic Overview

                14.2.1.5. SWOT Analysis

            14.2.2. Teva Pharmaceutical Industries Ltd.

                14.2.2.1. Company Description

                14.2.2.2. Business Overview

                14.2.2.3. Financial Overview

                14.2.2.4. Strategic Overview

                14.2.2.5. SWOT Analysis

            14.2.3. Amneal Pharmaceuticals, Inc.

                14.2.3.1. Company Description

                14.2.3.2. Business Overview

                14.2.3.3. Financial Overview

                14.2.3.4. Strategic Overview

                14.2.3.5. SWOT Analysis

            14.2.4. Pfizer, Inc.

                14.2.4.1. Company Description

                14.2.4.2. Business Overview

                14.2.4.3. Financial Overview

                14.2.4.4. Strategic Overview

                14.2.4.5. SWOT Analysis

            14.2.5. Mylan, Inc., (Viatris)

                14.2.5.1. Company Description

                14.2.5.2. Business Overview

                14.2.5.3. Financial Overview

                14.2.5.4. Strategic Overview

                14.2.5.5. SWOT Analysis

            14.2.6. Sanofi

                14.2.6.1. Company Description

                14.2.6.2. Business Overview

                14.2.6.3. Financial Overview

                14.2.6.4. Strategic Overview

                14.2.6.5. SWOT Analysis

            14.2.7. Johnson & Johnson (Johnson & Johnson Consumer, Inc.)

                14.2.7.1. Company Description

                14.2.7.2. Business Overview

                14.2.7.3. Financial Overview

                14.2.7.4. Strategic Overview

                14.2.7.5. SWOT Analysis

            14.2.8. Sun Pharmaceutical Industries Ltd.

                14.2.8.1. Company Description

                14.2.8.2. Business Overview

                14.2.8.3. Financial Overview

                14.2.8.4. Strategic Overview

                14.2.8.5. SWOT Analysis

            14.2.9. Environmental Tectonics Corporation

                14.2.9.1. Company Description

                14.2.9.2. Business Overview

                14.2.9.3. Financial Overview

                14.2.9.4. Strategic Overview

                14.2.9.5. SWOT Analysis

            14.2.10. Sechrist Industries, Inc.

                14.2.10.1. Company Description

                14.2.10.2. Business Overview

                14.2.10.3. Financial Overview

                14.2.10.4. Strategic Overview

                14.2.10.5. SWOT Analysis

    List of Tables

    Table 01: Radiation Proctitis: Clinical Trial Pipeline Analysis (1/2)

    Table 02: Radiation Proctitis: Clinical Trial Pipeline Analysis (2/2)

    Table 03: Estimated Number of Patients with Radiation Proctitis, by Key indications, by Key Countries 2020 (1/2)

    Table 04: Estimated Number of Patients with Radiation Proctitis, by Key indications, by Key Countries 2020 (2/2)

    Table 05: Global Radiation Proctitis Market Value (US$ Mn) Forecast, by Indication, 2018–2030

    Table 06: Global Radiation Proctitis Market Value (US$ Mn) Forecast, by Therapy, 2018–2030

    Table 07: Global Radiation Proctitis Market Value (US$ Mn) Forecast, by Oral Therapy, 2018–2030

    Table 08: Global Radiation Proctitis Market Value (US$ Mn) Forecast, by Region, 2018–2030

    Table 09: North America Radiation Proctitis Market Value (US$ Mn) Forecast, by Country, 2018–2030

    Table 10: North America Radiation Proctitis Market Value (US$ Mn) Forecast, by Indication, 2018–2030

    Table 11: North America Radiation Proctitis Market Value (US$ Mn) Forecast, by Therapy, 2018–2030

    Table 12: North America Radiation Proctitis Market Value (US$ Mn) Forecast, by Oral Therapy, 2018–2030

    Table 13: Europe Radiation Proctitis Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030

    Table 14: Europe Radiation Proctitis Market Value (US$ Mn) Forecast, by Indication, 2018–2030

    Table 15: Europe Radiation Proctitis Market Value (US$ Mn) Forecast, by Therapy, 2018–2030

    Table 16: Europe Radiation Proctitis Market Value (US$ Mn) Forecast, by Oral Therapy, 2018–2030

    Table 17: Asia Pacific Radiation Proctitis Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030

    Table 18: Asia Pacific Radiation Proctitis Market Value (US$ Mn) Forecast, by Indication, 2018–2030

    Table 19: Asia Pacific Radiation Proctitis Market Value (US$ Mn) Forecast, by Therapy, 2018–2030

    Table 20: Asia Pacific Radiation Proctitis Market Value (US$ Mn) Forecast, by Oral Therapy, 2018–2030

    Table 21: Latin America Radiation Proctitis Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030

    Table 22: Latin America Radiation Proctitis Market Value (US$ Mn) Forecast, by Indication, 2018–2030

    Table 23: Latin America Radiation Proctitis Market Value (US$ Mn) Forecast, by Therapy, 2018–2030

    Table 24: Latin America Radiation Proctitis Market Value (US$ Mn) Forecast, by Oral Therapy, 2018–2030

    Table 25: Middle East & Africa Radiation Proctitis Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030

    Table 26: Middle East & Africa Radiation Proctitis Market Value (US$ Mn) Forecast, by Indication, 2018–2030

    Table 27: Middle East & Africa Radiation Proctitis Market Value (US$ Mn) Forecast, by Therapy, 2018–2030

    Table 28: Middle East & Africa Radiation Proctitis Market Value (US$ Mn) Forecast, by Oral Therapy, 2018–2030

    List of Figures

    Figure 01: Global Radiation Proctitis Market Value (US$ Mn) Forecast, 2018–2030

    Figure 02: Global Radiation Proctitis Market Value Share, by Indication, 2019

    Figure 03: Global Radiation Proctitis Market Value Share, by Therapy, 2019

    Figure 04: Global Radiation Proctitis Market Value Share, by Region, 2019

    Figure 05: Global Radiation Proctitis Market Value Share Analysis, by Indication, 2019 and 2030

    Figure 06: Global Radiation Proctitis Market Attractiveness Analysis, by Indication, 2020–2030

    Figure 07: Global Radiation Proctitis Market Value (US$ Mn), by Acute Radiation Proctitis, 2018–2030

    Figure 08: Global Radiation Proctitis Market Value (US$ Mn), by Chronic Radiation Proctitis, 2018–2030

    Figure 09: Global Radiation Proctitis Market Value Share Analysis, by Therapy, 2019 and 2030

    Figure 10: Global Radiation Proctitis Market Attractiveness Analysis, by Therapy, 2020–2030

    Figure 11: Global Radiation Proctitis Market Value (US$ Mn), by Oral Therapy, 2018–2030

    Figure 12: Global Radiation Proctitis Market Value (US$ Mn), by Ablative Procedures, 2018–2030

    Figure 13: Global Radiation Proctitis Market Value (US$ Mn), by Hyperbaric Oxygen Therapy, 2018–2030

    Figure 14: Global Radiation Proctitis Market Value (US$ Mn), by Formalin, 2018–2030

    Figure 15: Global Radiation Proctitis Market Value (US$ Mn), by Surgery, 2018–2030

    Figure 16: Global Radiation Proctitis Market Value Share Analysis, by Region, 2019 and 2030

    Figure 17: Global Radiation Proctitis Market Attractiveness Analysis, by Region, 2020–2030

    Figure 18: North America Radiation Proctitis Market Value (US$ Mn) Forecast, 2018–2030

    Figure 19: North America Radiation Proctitis Market Value Share Analysis, by Country, 2019 and 2030

    Figure 20: North America Radiation Proctitis Market Attractiveness Analysis, by Country, 2020–2030

    Figure 21: North America Radiation Proctitis Market Value Share Analysis, by Indication, 2019 and 2030

    Figure 22: North America Radiation Proctitis Market Attractiveness Analysis, by Indication, 2020–2030

    Figure 23: North America Radiation Proctitis Market Value Share Analysis, by Therapy, 2019 and 2030

    Figure 24: North America Radiation Proctitis Market Attractiveness Analysis, by Therapy, 2020–2030

    Figure 25: Europe Radiation Proctitis Market Value (US$ Mn) Forecast, 2018–2030

    Figure 26: Europe Radiation Proctitis Market Value Share Analysis, by Country/Sub-region, 2019 and 2030

    Figure 27: Europe Radiation Proctitis Market Attractiveness Analysis, by Country/Sub-region, 2020–2030

    Figure 28: Europe Radiation Proctitis Market Value Share Analysis, by Indication, 2019 and 2030

    Figure 29: Europe Radiation Proctitis Market Attractiveness Analysis, by Indication, 2020–2030

    Figure 30: Europe Radiation Proctitis Market Value Share Analysis, by Therapy, 2019 and 2030

    Figure 31: Europe Radiation Proctitis Market Attractiveness Analysis, by Therapy, 2020–2030

    Figure 32: Asia Pacific Radiation Proctitis Market Value (US$ Mn) Forecast, 2018–2030

    Figure 33: Asia Pacific Radiation Proctitis Market Value Share Analysis, by Country/Sub-region, 2019 and 2030

    Figure 34: Asia Pacific Radiation Proctitis Market Attractiveness Analysis, by Country/Sub-region, 2020–2030

    Figure 35: Asia Pacific Radiation Proctitis Market Value Share Analysis, by Indication, 2019 and 2030

    Figure 36: Asia Pacific Radiation Proctitis Market Attractiveness Analysis, by Indication, 2020–2030

    Figure 37: Asia Pacific Radiation Proctitis Market Value Share Analysis, by Therapy, 2019 and 2030

    Figure 38: Asia Pacific Radiation Proctitis Market Attractiveness Analysis, by Therapy, 2020–2030

    Figure 39: Latin America Radiation Proctitis Market Value (US$ Mn) Forecast, 2018–2030

    Figure 40: Latin America Radiation Proctitis Market Value Share Analysis, by Country/Sub-region, 2019 and 2030

    Figure 41: Latin America Radiation Proctitis Market Attractiveness Analysis, by Country/Sub-region, 2020–2030

    Figure 42: Latin America Radiation Proctitis Market Value Share Analysis, by Indication, 2019 and 2030

    Figure 43: Latin America Radiation Proctitis Market Attractiveness Analysis, by Indication, 2020–2030

    Figure 44: Latin America Radiation Proctitis Market Value Share Analysis, by Therapy, 2019 and 2030

    Figure 45: Latin America Radiation Proctitis Market Attractiveness Analysis, by Therapy, 2020–2030

    Figure 46: Middle East & Africa Radiation Proctitis Market Value (US$ Mn) Forecast, 2018–2030

    Figure 47: Middle East & Africa Radiation Proctitis Market Value Share Analysis, by Country/Sub-region, 2019 and 2030

    Figure 48: Middle East & Africa Radiation Proctitis Market Attractiveness Analysis, by Country/Sub-region, 2020–2030

    Figure 49: Middle East & Africa Radiation Proctitis Market Value Share Analysis, by Indication, 2019 and 2030

    Figure 50: Middle East & Africa Radiation Proctitis Market Attractiveness Analysis, by Indication, 2020–2030

    Figure 51: Middle East & Africa Radiation Proctitis Market Value Share Analysis, by Therapy, 2019 and 2030

    Figure 52: Middle East & Africa Radiation Proctitis Market Attractiveness Analysis, by Therapy, 2020–2030

Copyright © Transparency Market Research, Inc. All Rights reserved